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Abstract
Background: The results of a small number of studies of autonomic function in patients with advanced cancer
suggest that autonomic dysfunction (AD) is common. In other disease-specific groups this is associated with
decreased survival, falls and symptoms such as postural hypotension, nausea, early satiety and fatigue. The
contribution of AD to symptoms in advanced cancer is unknown.
Methods: We conducted a prospective cohort study designed to identify the risk factors for falls in patients with
advanced cancer. Ambulant adult patients admitted consecutively to palliative care services were invited to
participate. Participants underwent an assessment at baseline which included standard clinical tests of autonomic
function, assessment of symptom severity, muscle strength, anthropometric measurements, walking speed,
medication use, comorbidities and demographics. Information regarding survival was recorded ten months
following cessation of recruitment. The clinical correlates of AD, defined as definite or severe dysfunction using
Ewing’s classification, were examined by univariate and multivariate logistic regression analysis. Survival analysis was
conducted using Kaplan-Meier plots and the log rank test.
Results: Of 185 patients recruited, 45% were unable to complete all of the clinical tests of autonomic function.
Non-completion was associated with scoring high on clinical indicators of frailty. It was possible to accurately
classify 138/185 (74.6%) of participants as having either definite or severe versus normal, early or atypical AD: 110
(80%) had definite/severe AD. In logistic regression analysis, age (OR = 1.07 [95% CI; 1.03-1.1] P = 0.001) and
increased severity of fatigue (OR = 1.26 [95% CI; 1.05-1.5] p = 0.016) were associated with having definite/severe
AD. In analysis adjusted for age, median survival of participants with definite/severe AD was shorter than in those
with normal/early/atypical classification (c
2 = 4.3, p = 0.038).
Conclusions: Autonomic dysfunction is highly prevalent in patients with advanced cancer and is associated with
increased severity of fatigue and reduced survival. Due to frailty, up to 45% of participants were unable to
complete standard clinical tests of autonomic function. In order to further investigate the impact of AD and the
therapeutic potential of treatment of AD in patients with advanced cancer, the validity of alternative novel
methods of assessing autonomic function must be appraised.
Background
The autonomic nervous system innervates blood vessels,
the airways, intestines and urogenital organs and is lar-
gely under involuntary control. It regulates and coordi-
nates bodily functions by effecting secretory activity of
glands and contraction and relaxation of smooth and
cardiac muscle [1]. Autonomic neuropathy may be idio-
pathic or occur as a complication of other conditions or
as result of drugs. It is recognised as a common compli-
cation in patients with diabetes mellitus; for many it
remains subclinical, with only a minority experiencing
symptoms such as postural hypotension, nausea, vomit-
ing and early satiety related to gastroparesis, nocturnal
diarrhoea, bladder-emptying problems and male erectile
dysfunction [2]. Autonomic dysfunction (AD) has also
been shown to be a negative prognostic indicator
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The underlying mechanism is thought to be an
increased risk of cardiac arrhythmias as a result of
decreased vagal tone [4]. Although the autonomic ner-
vous system innervates all organs, due to the serious
implications of cardiovascular autonomic dysfunction,
investigation of autonomic function involving the cardi-
ovascular system has become most established [5].
Autonomic dysfunction has been described in patients
with advanced cancer, in whom a high prevalence of
AD is identified [6-9]. Postulated causes include
decreased physical activity, treatment with vinca alka-
loids or other medications, or paraneoplastic processes
[10,11]. The precise contribution of AD to clinical find-
ings and prognosis in advanced cancer is unclear. Only
one study has demonstrated a relationship between AD
and symptoms in patients with advanced cancer; Bruera
et al found that patients with advanced breast cancer in
whom all tests of cardiovascular autonomic function
were abnormal were more likely to report symptoms of
postural hypotension and chronic unexplained nausea
[6,7,9]. More recent research on AD in advanced cancer
has focussed on its prognostic significance; a small num-
ber of studies have identified a relationship between AD
and shorter survival in advanced cancer [12-14].
Cardiovascular autonomic neuropathy has been shown
to be a risk factor for falls in older adults with dementia
[15]. We conducted a prospective study of the risk fac-
tors for falls in patients with advanced cancer. In view
of the reported high prevalence of AD in patients with
advanced cancer we elected to include tests of cardio-
vascular autonomic function in our research assessment.
Autonomic function is most commonly measured by the
application of a group of clinical tests, which aim to mea-
sure sympathetic and parasympathetic activity, by mea-
suring end-organ responses to physiological perturbations
[16]. Ewing et al devised a battery of four tests which
generate three outcome measures of parasympathetic
activity and two of sympathetic activity, the results of
which can be used to grade the severity of autonomic
dysfunction [17]. In this paper we specifically report our
findings in relation to the frequency and clinical corre-
lates of AD, highlight and evaluate the difficulties experi-
enced in measuring autonomic function in patients with
advanced cancer, and make recommendations regarding
the direction of future research in this area.
Methods
Setting and participants
Eligible patients who were admitted consecutively to the
palliative care services provided by Our Lady’sH o s p i c e
and Care Services (November 24, 2008 - Dec 24, 2010)
were invited to participate. The palliative care services
consist of inpatient care provided in a 36-bed inpatient
unit (IPU), a day hospice service and a home care ser-
vice. Patients aged 18 years or older with a diagnosis of
metastatic or loco-regionally advanced cancer were eligi-
ble for inclusion. Exclusion criteria were as follows:
being unable to stand and mobilize unassisted, actively
dying or considered too unwell by the admitting and
research teams, registered blind, using continuous oxy-
gen, and being aphasic or unable to converse in English.
Eligible patients received written information on the
study at the time of admission to services. Enrolment of
patients with impaired cognition (Short Orientation-
Memory Concentration Test (SOMCT) score greater
than 11) required the assent of the patient in addition
to consent from their proxy. The SOMCT error score
ranges from 0-28; the normal score range is 0-6 [18].
All other participants provided informed consent. The
study was approved by St. Vincent’s University Health
Group Ethics Committee.
Data collection
Demographic details, comorbidities and medications
were transcribed from admission notes and verified at
patient interview. The following were considered to be
cardioactive medications; beta blockers, tricyclic antide-
pressants, nitrates, rate-limiting calcium antagonists,
anticholinergics and other antiarrhythmics. Performance
status was recorded using the Palliative Performance
Scale (PPS) [19].
All assessments were conducted between 0900 h and
1300 h. All participants were asked to refrain from
smoking and caffeine ingestion on the morning of
assessment, but were not asked to stop any of their
usual medications or fast. A physician and research
nurse performed the tests of autonomic function in a
quiet room at ambient temperature (21-23 C). Auto-
nomic function tests were carried out using a modified
Ewing’s battery [17]. Heart rate was measured by ECG
using standard limb leads; heart rate (HR) tests were
excluded if invalidated by arrhythmia, excessive ectopic
activity or movement artefact. Blood pressure (BP) was
monitored using the Finometer Pro device (Finapres
Medical Systems BV, Amsterdam, the Netherlands)
which enables noninvasive beat-to-beat BP measurement
from finger arterial BP. The BP recordings are derived
from the circumferential pressure generated by a finger
cuff, which is varied to maintain a constant digital arter-
ial size, as measured by a photoplethysmograph. Under
such conditions the external cuff pressure equals the
internal digital arterial pressure [20]. Participants rested
in the supine position for at least ten minutes before
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ket and wore a thermal mitten with glove liner in order
to improve BP signal pick-up. Blood pressure tests were
excluded if the trace was obscured by movement arte-
fact or artefact due to external pressure on the finger-
cuff.
Parasympathetic tests
1. Deep breathing
Whilst supine, participants were requested to ‘take
slow deep breaths, so that each breath in lasts five
seconds and each breath out lasts 5 s, for a total of
six consecutive breaths’. This was rehearsed prior to
testing and the tester guided the timing of the
breaths for the participant by verbally counting
through each of the six breaths/cycles. The maxi-
mum and minimum HR during each breathing cycle
was calculated from the corresponding shortest and
longest R-R interval, and the response recorded as
the mean of the differences during three successive
breathing cycles.
2. Active stand
Participants were requested to stand up from the
supine position as quickly as possible and to remain
standing, in silence, for three minutes, with the
monitored arm resting by their side. Assistance with
rising was provided when this could not be achieved
independently. Heart rate response was measured as
the ratio of the maximum R-R interval at or around
the 30
th beat after starting to stand, to the minimum
R-R interval at or around the 15
th beat.
3. Valsalva manoeuvre
The valsalva manoeuvre was achieved by forced
expiration, against an open glottis. Participants were
requested to achieve a constant pressure of 40
mmHg for 15 s. The procedure was rehearsed prior
to testing and the tester guided the participant by
counting aloud through the fifteen seconds. The test
was performed three times and the best response
used for analysis. A minimum of one test achieving
30 mmHg for 12 s was required for inclusion. Heart
rate response was taken as the ratio of the maximum
R-R interval shortly after the manoeuvre to the mini-
mum R-R interval during the procedure.
Sympathetic test
1. Active stand
T h ec h a n g ei nB Pw a sm e a s u r e da st h ed i f f e r e n c e
between the baseline BP whilst supine and the low-
est BP after standing.
Results for the valsalva manoeuvre were graded as
normal or abnormal, and all other tests as normal, bor-
derline or abnormal using the values recommended by
Ewing et al [17]. Overall autonomic function was
described using Ewing’s classification system:
￿ Normal: all tests normal or one borderline
￿ Early dysfunction: one of the three HR tests abnor-
mal or two borderline
￿ Definite dysfunction: two or more HR tests
abnormal
￿ Severe dysfunction: two or more HR tests abnormal
plus one BP test abnormal or both borderline
￿ Atypical pattern: any other combination of abnormal
tests [17].
Severity of tiredness, nausea, loss of appetite and
shortness of breath were measured using the Edmon-
ton Symptom Assessment Scale; an 11 point numerical
rating scale from 0-10, whereby larger numbers repre-
sent increased symptom severity [21]. Information
regarding survival of study participants was obtained
from an electronic palliative care patient administration
database system, used by Our Lady’s Hospice & Care
Services and the hospitals within its catchment area.
Survival in days was measured from the day of assess-
ment. The analysis of survival times was conducted on
Sept 24, 2011.
BMI was calculated from participants’ height and
weight as measured on the day of assessment, and weight
loss by subtracting current weight from reported weight
prior to cancer diagnosis. Walking speed was measured
using the timed ‘Up and Go’ (TUAG) whereby the parti-
cipant is asked to rise from a seated position, walk to a
marked spot three metres away, turn around and return
to their seat. The participant is instructed to walk at their
normal pace and may use any gait aid normally used.
Timing is started when the participant is instructed to
‘go’ and stopped when they are seated in the chair again
[22]. Grip strength was measured 3 times in each hand
using a hydraulic hand dynamometer (Jamar, Samons
Preston Rolyan, Bolingbrook, IL). The result used was the
best result of the six measurements.
Statistical methods
Demographic details and clinical variables were sum-
marised using descriptive statistics. Comparisons of
groups of categorical variables were conducted using the
Chi-squared test, of normally distributed continuous
variables using the 2-sample t-test and of non-para-
metric variables using the Mann-Whitney U test. Vari-
ables shown to be associated with AD in univariate
analyses, with p < 0.1, were entered into logistic regres-
sion models, using forwards and backwards stepwise
variable entry. Only variables that were significant at p <
0.05 were retained in the model. The relationship
between AD and survival was examined using survival
analysis methods, including the log rank test.
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During the study period, there were 1,607 admission
episodes involving 1,117 individuals, of whom 693 (62%)
were ineligible, 239 (21.4%) declined and 185 (16.6%)
were recruited. There were no significant demographic
differences between participants and those who declined
(see Table 1).
Completion of individual components of Ewing’s battery
HR response to deep breathing
The HR data of 14/185 (7.6%) participants were invali-
dated by arrhythmia. A further nine participants were
unable to complete three consecutive breaths according
to the study protocol, due to inattention and/or diffi-
culty understanding and retaining information. The
median SOMCT error score in those who completed
the test was 2 compared with 6.5 (p = 0.015) in those
who did not complete it.
HR response to active stand
The HR data of 14/185 (7.6%) participants were invali-
dated by arrhythmia and one other by excessive artefact
at the time of standing.
BP response to active stand
The BP data of 42/185 (22.7%) participants was invali-
dated due to failure to obtain a good quality trace or
due to artefact; most commonly due to external pressure
on the finger cuff at the time of the stand.
HR response to valsalva manoeuvre
Eighty-three (45%) participants were unable to complete
the valsalva manoeuvre. We conducted analyses to
explore our post-hoc hypothesis that the high prevalence
of non-completion of the valsalva manoeuvre was due
to the phenotypic characteristics of our study popula-
t i o n .W eo b s e r v e dt h a tp a t i e n t sw h oh a df e a t u r e s
consistent with the geriatric syndrome of frailty [23]
were less likely to be able to complete the valsalva man-
oeuvre. See Table 2 for results. In view of the high pre-
valence of dyspnoea in advanced cancer we included the
ESAS item on severity of shortness of breath in our ana-
lysis, but found that this was not associated with ability
to complete the valsalva manoeuvre.
Prevalence of autonomic dysfunction and associated
factors
Due to the high levels of missing data pertaining to the
HR response to valsalva manoeuvre and BP response to
active stand, it was only possible to accurately define
autonomic function, using Ewing’s classification (nor-
mal, definite, severe or atypical), for 91/185 (49.2%)
participants. See Figure 1. By collapsing the Ewing’s
classification into a binary classification of definite/
severe versus other, it was possible to accurately clas-
sify 138/185 (74.6%) participants as having either nor-
mal, early or atypical, (other category) versus definite
or severe AD. Of 138 patients 110 (80%) had definite
or severe AD. Having definite/severe AD was asso-
ciated with poor performance status (c
2 for trend =
8.2, p = 0.004) and increasing age; see Table 3 for con-
tingency table of binary AFT classification according to
age groups defined by quartiles (c
2 for trend = 7.6, p =
0.006). In univariate analysis, gender, taking cardioac-
tive medication and having a diagnosis of diabetes mel-
litus were not associated with binary AFT classification
(c
2 =0 . 1 7 ,p =0 . 7 ,c
2 =0 . 8 9 ,p =0 . 4a n dc
2 =0 . 4 ,p =
0.5 respectively), whereas having at least one cardiovas-
cular comorbidity was associated with having definite/
severe AD (c
2 = 3.79, p = 0.05). Having definite/severe
AD was associated with severity of tiredness as mea-
sured using the ESAS (median 4/10 versus 2/10, p =
0.006), but not with severity of appetite loss (median 3/
10 versus 1/10, p = 0.07) or nausea (median 0/10 ver-
sus 0/10, p = 0.9). Age, PPS, taking cardioactive medi-
cations, severity of tiredness (ESAS) and severity of
appetite loss (ESAS) were entered into the logistic
regression models. However, only age (OR = 1.07 [95%
CI; 1.03-1.1] P = 0.001) and severity of tiredness (OR =
1.26 [95% CI; 1.05-1.5] p =0 . 0 1 6 )w e r es h o w nt ob e
significantly associated with a diagnosis of definite or
severe autonomic dysfunction.
The median survival for participants with definite/
severe AD was 106 days (95% CI; 78.6-133.4) compared
with 135 days (95% CI; 24.8-245.2) in those with nor-
mal/early/atypical classification (c
2 = 4.8, p = 0.028). See
Figure 2. The relationship between AD and survival per-
sisted in analysis adjusted for age, defined by quartiles
as above (c
2 = 4.3, p = 0.038).
Table 1 Demographic details of participants and those
who declined participation
Participants
(n = 185)
Declined
(n = 239)
Analysis
Gender Male (%) 52.4 50.2 c
2 = 0.2, 1df
p = 0.65
Age (years) 68 ± 12.6 68.3 ± 13.1 t = 0.12,
p = 0.9
Cancer diagnosis (%)
Bronchial 18.4 23.4 c
2 = 5.7,
Breast 14.1 12.1 9df
Lower GI 14.1 13.8 p = 0.8
Upper GI 11.4 10.9
Prostate 9.7 7.1
Gynaecological 7 6.3
Pancreatic/hepatobiliary 6.5 8.8
Urological not prostate 5.4 4.6
Brain 2.7 0.8
Other 10.8 12.1
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valid active stand BP data had a systolic BP drop of at
least 30 mmHg on standing.
Discussion
Using Ewing’s classification it was possible to diagnose
the presence or absence of definite or severe AD in 138/
185 (74.6%) participants, of whom 80% had definite/
severe AD. This finding is consistent with the preva-
lence of moderate/severe AD measured in patients with
advanced cancer (n = 50), as reported by Walsh and
Nelson, and in men with advanced cancer (n = 48), as
reported by Strasser et al of 82% and 81%, respectively
[7,9]. In our study, severity of fatigue was greater in
patients with definite/severe AD, and although ESAS
scores for loss of appetite were greater in those with
definite/severe AD, this did not reach statistical signifi-
cance. Median ESAS scores for nausea were zero in
both groups, which most likely reflects the availability of
effective treatment for this symptom. Having definite/
severe AD was associated with shorter survival.
Although this confirms the findings of previous studies
of AD in patients with advanced cancer, it has yet to be
clarified whether AD causes shorter survival or if factors
associated with shorter survival, such as increased time
spent in bed, contribute to severity of AD.
A striking finding of our study was the poor feasibility
of conducting autonomic function testing, using Ewing’s
battery, in patients with advanced cancer. Forty-five per-
cent of patients were unable to complete the valsalva
manoeuvre, despite our having adopted a lower thresh-
old for the duration, pressure and number of tests
Table 2 Features of participants according to whether they were able to complete the valsalva manoeuvre
Variable Mean/median
Valsalva completed
Mean/median
Valsalva not completed
P value
Weight loss (Kg) 4.3 7.8 0.09 (t = -1.7)
BMI 26 22.6 < 0.0001 (t = 4.9)
TUAG (secs) 14.06* 18.7* < 0.0001
Grip strength (kg) 24.5* 18.0* < 0.0001
Tiredness (ESAS) 3* 4* 0.2
Age (years) 65.4 71.5 0.001 (t = -3.3)
*Median value
Figure 1 Pie chart to show prevalence of autonomic dysfunction in patients with advanced cancer (n = 91).
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analyses supported our observation that more frail
patients were less likely to be able to complete the val-
salva manoeuvre. Prior to the active stand, participants
were requested not to grip anything with their right
hand during the process of rising or during the three
minute stand: most participants did receive the assis-
tance of one of the testers to rise from the supine to
seated position. Despite this many participants experi-
enced difficulty with getting up quickly. Additionally, we
took steps to ensure a good digital BP recording by
keeping the participant warm prior to testing. Despite
this, BP data from 23% of participants were invalid,
mainly due to artefact from external pressure on the fin-
ger cuff at the time of standing or due to a poor quality
trace.
Walsh and Nelson reported that participants in their
study also had difficulty with rising from a supine posi-
tion to standing, and that they found the valsalva man-
oeuvre stressful, but despite this 48/50 (96%) patients
managed to complete it [7]. Bruera et al reported that
8/43 (18.6%) participants had missing HR and BP data
for the active stand as they were unable to stand up
readily. It is likely that our use of beat-to-beat BP mea-
surement from finger arterial BP, though now the stan-
dard in clinical and research autonomic function
laboratories, resulted in our relatively high rate of failure
in obtaining active stand BP data in this patient popula-
tion. All other studies in patients with advanced cancer
measured BP at the brachial artery with a sphygmoman-
ometer, which has the drawback of not providing con-
tinuous monitoring, but is less susceptible to artefact
Table 3 Binary AFT classification according to age (quartiles)
Age Group Total
< 58 yrs 58-67 yrs 68-76 yrs ≥ 77 yrs
Normal/early/atypical AFT classification Count Expected count 14
6.3
5
7.3
3
7.1
6
7.3
28
28
Definite/severe AFT classification Count Expected count 17
24.7
31
28.7
32
27.9
30
28.7
110
110
Total Count Expected count 31
31
36
36
35
35
36
36
138
138
Figure 2 Kaplan-Meier plot to show relationship between survival and autonomic function (n = 138).
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vasoconstriction.
Our use of a modified version of the Ewing’s battery
of tests was a notable study limitation: we omitted a sec-
ond test of sympathetic function, the BP response to
isometric exercise, whereby the patient is instructed to
grasp a dynamometer and sustain a fixed, isometric con-
traction for 3 min at 30% maximum effort. We omitted
this test for pragmatic reasons: an accurate diagnosis of
definite AD according to Ewing’s classification can be
made based on 3 HR tests; this test had the lowest rate
of completion in Walsh and Nelson’s earlier study, as
participants found it difficult. Furthermore, this test has
been shown to have low sensitivity and specificity, due
to problems standardising muscular effort and variability
in muscle afferent activity when tested in trained versus
untrained muscles [7,16].
The ranges for normal values for each test were
derived by Ewing from tests in healthy subjects aged 16-
69 years [17]. However, HR responses to deep breathing,
active stand and the valsalva manoeuvre decline with
age. Our use of Ewing’s normal values, rather than
determining age-specific normal values from testing age-
matched controls, may have resulted in false negative
test results in younger patients and also means that we
cannot isolate the effect of a diagnosis of advanced can-
cer from the effect of normal aging on AD. Despite this,
54.8% of those aged less than 58 years were classified as
having definite/severe AD. Unlike previous studies, we
did not exclude patients who had other medical conditions
known to be associated with AD or those taking medica-
tions which may affect autonomic reflexes. However, we
found that in the context of advanced cancer, these condi-
tions do not significantly increase the risk of AD.
Autonomic dysfunction is common in patients with
advanced cancer. The findings of Bruera et al suggest
that AD may be associated with symptoms of postural
hypotension and unexplained nausea [6]. In view of the
high prevalence of orthostatic hypotension (OH) in this
study, we recommend routine enquiry for symptoms
suggestive of OH and measurement of lying and stand-
ing BP in patients with advanced cancer. Management
of OH includes discontinuation of antihypertensive
medication, adoption of physical counter- manoeuvres,
and use of mineralocorticoid (e.g. fludrocortisone) and/
or adrenergic agonist (e.g. midodrine) medications [24].
For patients with unexplained symptoms suspected to
be due to AD involving other systems, targeted investi-
gation, such as gastric emptying studies in patients with
chronic unexplained nausea, should be considered [25].
In this study, patients with definite or severe AD had
higher scores for severity of tiredness, as measured by
the ESAS. Fatigue has been shown to be associated with
AD in patients with Multiple Sclerosis and Primary
Biliary Cirrhosis [26,27]. Impaired autonomic function
has also been described in patients with Chronic Fatigue
Syndrome (CFS) [28,29] and patients with vasovagal
syncope (VVS) have been shown to have higher levels of
fatigue than age-matched controls [30]. A postulated
explanation for these associations is that fatigue occurs
as a result of impaired organ perfusion related to hypo-
tension [30]. Alternative explanations, in the case of
CFS, are that AD develops as a result of reduced physi-
cal activity, or that both the fatigue and AD have a com-
mon aetiology. However, early studies in patients with
CFS and VVS suggest that severity of fatigue may
improve with treatment of AD related postural hypoten-
sion. In a cross-sectional study of patients with VVS
diagnosed and treated by a single Falls and Syncope Ser-
vice (n = 91), patients whose syncopal symptoms had
responded to conventional treatment (conservative
advice, followed three months later in the event of per-
sistent symptoms, by commencement of either fludro-
cortisone, midodrine or a selective serotonin reuptake
inhibitor) reported less severe fatigue and daytime slee-
piness than those with persistent syncopal symptoms
[30]. In a pilot study of 10 patients with CFS shown to
have abnormal cardiovascular responses to a head-up
tilt test, for 6 patients, treatment with midodrine
resulted in normalisation of cardiovascular responses at
three months, followed by an improvement in fatigue
scores 4-8 weeks later [31]. Exploration of the relation-
ship between autonomic dysfunction and fatigue, the
potential for reversibility of AD with pharmacological
intervention, and the impact of this on fatigue and sur-
vival in patients with advanced cancer, are all worthy of
further investigation.
However, in view of our findings relating to the feasibil-
ity of conducting standard clinical tests of autonomic
function in a large cohort of patients with advanced can-
cer, we recommend that the reliability and validity of
novel methods of assessment of autonomic function are
investigated further. The findings of Fadul et al suggest
that measurement of heart rate variability (HRV) may
provide a useful measure of AD in this population, for
both research and clinical purposes. Power spectral analy-
sis of heart rate fluctuations, recorded by continuous
electrocardiogram, provide a simple and non-invasive
technique for analysing autonomic function. In their
study of men with advanced cancer, Fadul et al found a
strong association between the results of the Ewing’s bat-
tery and the time domain measure ‘standard deviation of
normal to normal beat interval’ (r = 0.44,p= 0.002) [13].
Conclusions
Autonomic dysfunction is highly prevalent in advanced
cancer and is associated with severity of fatigue and
shorter survival. Research findings in patients with VVS
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tion may result in alleviation of fatigue. Future research
on the impact of AD and its treatment in patients with
advanced cancer must also address the potential for
novel methods of assessment of autonomic function to
provide a reliable proxy for the standardised clinical
tests; due to frailty, 45% of participants in this study
were unable to complete Ewing’s battery of tests empha-
sising the need to explore alternative methods for eva-
luation of autonomic function in this population.
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